Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage Diagnosis

Background: Bladder cancer (BC) ranks as the tenth most common cancer globally, with a high recurrence rate. It is primarily caused by abnormalities in the epithelial layer lining the bladder and is classified from non-muscle invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MI...

Full description

Saved in:
Bibliographic Details
Main Authors: Hosam Elessawy, Omar F. Abdul‐Rasheed, Mohammed F. Alqanbar
Format: Article
Language:English
Published: University of Baghdad/ Al-Kindy College of Medicine 2025-04-01
Series:مجله كليه طب الكندي
Subjects:
Online Access:https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1855
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850262504254472192
author Hosam Elessawy
Omar F. Abdul‐Rasheed
Mohammed F. Alqanbar
author_facet Hosam Elessawy
Omar F. Abdul‐Rasheed
Mohammed F. Alqanbar
author_sort Hosam Elessawy
collection DOAJ
description Background: Bladder cancer (BC) ranks as the tenth most common cancer globally, with a high recurrence rate. It is primarily caused by abnormalities in the epithelial layer lining the bladder and is classified from non-muscle invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC). Fibroblast Growth Factor Receptor 3 (FGFR3) S249C mutation is frequently observed in low-grade NMIBC but are rare in high-grade NMIBC and MIBC, leading to continuous receptor activation and promoting tumor growth. Objective: This study aims to investigate the prevalence of FGFR3 S249C mutation in Iraqi BC patients, assess their association with tumor stage and grade, evaluate the potential of FGFR3 mutation as an early-stage diagnostic marker, and discuss implications for public health policy. Subjects and Methods:  The study was conducted at Al-Safeer Hospital, Karbala, Iraq. It included 60 individuals diagnosed with urothelial BC (50 males, 83.3%; 10 females, 16.4%) with a median age of 63 years. Tumor tissue samples from patients undergoing Transurethral Resection of Bladder Tumor (TURBT) were used. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue samples, and FGFR3 mutations were examined through direct DNA sequencing, focusing on the S249C mutation in exon 7. The prevalence of the S249C mutation was analyzed in relation to tumor stage and grade. Results: The study revealed a significant prevalence (55%) of the S249C mutation. This mutation was more frequent among males and individuals over the age of 50 years. There was a higher incidence of BC in males (83.3%) compared to females (16.7%), especially in those aged 50 years and older. Histomorphological evaluations showed a considerable number of tumors classified as low-grade. Furthermore, pathological staging results identified pT1 as the most common stage, followed by pTa and pT2, underscoring the predominance of early-stage tumors within the study population. Conclusions: This study highlighted the significant prevalence of FGFR3 S249C mutation in Iraqi BC patients. FGFR3 mutations were strongly associated with early-stage and low-grade tumors, indicating their potential as a molecular marker for early diagnosis.
format Article
id doaj-art-00aac84d49da434ab06fd59ffdce4cba
institution OA Journals
issn 1810-9543
2521-4365
language English
publishDate 2025-04-01
publisher University of Baghdad/ Al-Kindy College of Medicine
record_format Article
series مجله كليه طب الكندي
spelling doaj-art-00aac84d49da434ab06fd59ffdce4cba2025-08-20T01:55:11ZengUniversity of Baghdad/ Al-Kindy College of Medicineمجله كليه طب الكندي1810-95432521-43652025-04-0121110.47723/cp575x891781Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage DiagnosisHosam Elessawy0Omar F. Abdul‐Rasheed1https://orcid.org/0000-0003-3016-9176Mohammed F. Alqanbar2https://orcid.org/0009-0002-1723-0112Department of Biochemistry, College of Medicine, University of Al-Nahrain, Baghdad, IraqDepartment of Biochemistry, College of Medicine, University of Al-Nahrain, Baghdad, IraqDepartment of Chemistry and Biochemistry, Faculty of Medicine, Al-Nahrain University, Baghdad, Iraq Background: Bladder cancer (BC) ranks as the tenth most common cancer globally, with a high recurrence rate. It is primarily caused by abnormalities in the epithelial layer lining the bladder and is classified from non-muscle invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC). Fibroblast Growth Factor Receptor 3 (FGFR3) S249C mutation is frequently observed in low-grade NMIBC but are rare in high-grade NMIBC and MIBC, leading to continuous receptor activation and promoting tumor growth. Objective: This study aims to investigate the prevalence of FGFR3 S249C mutation in Iraqi BC patients, assess their association with tumor stage and grade, evaluate the potential of FGFR3 mutation as an early-stage diagnostic marker, and discuss implications for public health policy. Subjects and Methods:  The study was conducted at Al-Safeer Hospital, Karbala, Iraq. It included 60 individuals diagnosed with urothelial BC (50 males, 83.3%; 10 females, 16.4%) with a median age of 63 years. Tumor tissue samples from patients undergoing Transurethral Resection of Bladder Tumor (TURBT) were used. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue samples, and FGFR3 mutations were examined through direct DNA sequencing, focusing on the S249C mutation in exon 7. The prevalence of the S249C mutation was analyzed in relation to tumor stage and grade. Results: The study revealed a significant prevalence (55%) of the S249C mutation. This mutation was more frequent among males and individuals over the age of 50 years. There was a higher incidence of BC in males (83.3%) compared to females (16.7%), especially in those aged 50 years and older. Histomorphological evaluations showed a considerable number of tumors classified as low-grade. Furthermore, pathological staging results identified pT1 as the most common stage, followed by pTa and pT2, underscoring the predominance of early-stage tumors within the study population. Conclusions: This study highlighted the significant prevalence of FGFR3 S249C mutation in Iraqi BC patients. FGFR3 mutations were strongly associated with early-stage and low-grade tumors, indicating their potential as a molecular marker for early diagnosis. https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1855Bladder CancerFormalin Fixed Paraffin-Embedded SamplesIraqi bladder cancerFGFR3 S249C Mutation
spellingShingle Hosam Elessawy
Omar F. Abdul‐Rasheed
Mohammed F. Alqanbar
Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage Diagnosis
مجله كليه طب الكندي
Bladder Cancer
Formalin Fixed Paraffin-Embedded Samples
Iraqi bladder cancer
FGFR3 S249C Mutation
title Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage Diagnosis
title_full Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage Diagnosis
title_fullStr Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage Diagnosis
title_full_unstemmed Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage Diagnosis
title_short Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage Diagnosis
title_sort fibroblast growth factor receptor 3 mutations in bladder cancer a marker for early stage diagnosis
topic Bladder Cancer
Formalin Fixed Paraffin-Embedded Samples
Iraqi bladder cancer
FGFR3 S249C Mutation
url https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1855
work_keys_str_mv AT hosamelessawy fibroblastgrowthfactorreceptor3mutationsinbladdercanceramarkerforearlystagediagnosis
AT omarfabdulrasheed fibroblastgrowthfactorreceptor3mutationsinbladdercanceramarkerforearlystagediagnosis
AT mohammedfalqanbar fibroblastgrowthfactorreceptor3mutationsinbladdercanceramarkerforearlystagediagnosis